A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Part of paid clinical trials in St Louis, Missouri.
- Sponsor
- BicycleTx Limited
- Study ID
- NCT07450859
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- nuzefatide pevedotin (BT5528) — DRUGParticipants will receive nuzefatide pevedotin (BT5528) via intravenous (IV) infusion every 2 weeks (Q2W)
Study Details
This is a Phase 2 study for nuzefatide pevedotin (BT5528) in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment. The drug, nuzefatide pevedotin (nuzefatide), is designed to find a specific protein called EphA2. The main aims of the study are to see how well the drug works against the tumor (efficacy), what side effects it may have (safety), and how the body processes it (pharmacokinetics). All participants in this study will receive nuzefatide, and both they and their doctors will know what is being administered (single-arm, open-label). The trial will take place at several different medical centers.
Key Dates
- First listed
- Mar 5, 2026
- Start date
- Mar 5, 2026
- Status verified
- Apr 2026
- Primary completion
- Mar 31, 2029
- Completion
- May 31, 2029
Study Design
- Enrollment
- 39 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: nuzefatide pevedotin (BT5528) Monotherapy
Primary Outcome Measure
Objective Response Rate (ORR) [ Time Frame: Up to approximately 3 years ]
Central Contacts
- BicycleTx Limited6179458155
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Siteman Cancer Center (Washington University School of Medicine) | St Louis | Missouri | 63108 | Kian-Huat Lim |
| Memorial Sloan Kettering Cancer Center - Main Campus | New York | New York | 10065 | Kenneth Yu 646-888-4188 |
| Thomas Jefferson University, Sidney Kimmel Comprensive Cancer Center, Clinical Trials Office | Philadelphia | Pennsylvania | 19107 |
Find similar trials in St Louis, MO
Related Studies
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASPHASE1/PHASE2 · Recruiting · Revolution Medicines, Inc. · Orange, California
- KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsPHASE1 · Recruiting · Kura Oncology, Inc. · Phoenix, Arizona
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsPHASE1 · Recruiting · Revolution Medicines, Inc. · Sacramento, California
- Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)PHASE3 · Recruiting · SOFIE · Cerritos, California